Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imugene ( (AU:IMU) ) has shared an announcement.
Imugene Limited has applied for quotation on the ASX of 1,736,111 new fully paid ordinary shares, with an issue date of 22 December 2025. The additional securities, issued under a previously announced transaction, will increase the company’s quoted share capital, potentially enhancing liquidity in its stock and supporting ongoing corporate and capital management activities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an ASX-listed biotechnology company focused on developing immuno-oncology therapies. The company operates in the biopharmaceutical industry, with its primary activities centred on the research and development of cancer treatments targeting the immune system, aimed at global oncology markets.
YTD Price Performance: -75.76%
Average Trading Volume: 1,859,614
Technical Sentiment Signal: Sell
Current Market Cap: A$96.19M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.